Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Ardelyx Inc. buy WatchMen

Start price
€4.91
13.12.23 / 0%
Target price
-
13.12.24
Performance (%)
64.52%
Price
€8.08
03.05.24
Summary
This prediction is currently active. With a performance of 64.52% the BUY prediction by WatchMen is a big success. This prediction currently runs until 13.12.24. The prediction end date can be changed by WatchMen at any time.

Ardelyx, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines aimed at treating kidney and cardiovascular diseases. The company uses a unique approach to drug discovery, developing therapeutics that target ion channels and transporters, which play a critical role in regulating activities in the body. Ardelyx's lead product candidate, tenapanor, is being studied for the treatment of conditions such as hyperphosphatemia in patients with chronic kidney disease, irritable bowel syndrome with constipation, and diverticulosis. The company is listed on the NASDAQ exchange under the ticker symbol ARDX.

Performance without dividends (%)
Name 1w 1m
Ardelyx Inc. 34.723% 34.723%
iShares Core DAX® -0.922% -1.993%
iShares Nasdaq 100 0.371% -0.868%
iShares Nikkei 225® 2.224% -5.187%
iShares S&P 500 -0.026% -0.918%

Comments by WatchMen for this prediction

In the thread Ardelyx Inc. diskutieren
Prediction Buy
Perf. (%) 64.52%
Target price 10.000
Change
Ends at

Buy mit Kursziel 10,0

Prediction Buy
Perf. (%) 64.52%
Target price 20.000
Change
Ends at 13.12.24

Kursziel geändert auf 20,0

Prediction Buy
Perf. (%) 64.52%
Target price
Change
Ends at 13.12.24

Kursziel geändert auf 0,0

Prediction Buy
Perf. (%) 64.52%
Target price 20.000
Change
Ends at 13.12.24

Kursziel gesetzt auf 20,0

Prediction Buy
Perf. (%) 64.52%
Target price
Change
Ends at 13.12.24

Kursziel geändert auf 0,0